Altre lingue Pulse Biosciences, Inc.

Azioni

PLSE

US74587B1017

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 30/04/2024			Variaz. 5gg	Var. 1 gen.
7,37 ^USD	+1,66%		+7,43%	-39,79%

01/04	Aggiornamento settoriale: i titoli del settore sanitario scivolano nel tardo pomeriggio	MT
01/04	Le azioni di Pulse Biosciences scendono dopo i risultati del quarto trimestre, i piani di emissione di diritti	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024	24/04
Sector Update: Health Care Stocks Slide Late Afternoon	01/04
Pulse Biosciences Shares Fall After Q4 Results, Rights Issue Plans	01/04
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03
Pulse Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03
Pulse Biosciences Announces Plans to Initiate a Rights Offering	28/03
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024	14/03
Sector Update: Health Care Stocks Ease Late Afternoon	08/03
Pulse Biosciences Gets FDA Clearance For Percutaneous Electrode System	08/03
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System	08/03
Pulse Biosciences, Inc. Announces FDA 510(K) Clearance for its CellFX nsPFA Percutaneous Electrode System	08/03
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY	15/02
Pulse Biosciences, Inc. Announces Positive 60-Day Follow-Up Evaluations for Initial Patients Treated in the Cellfx Nspfa 360° Cardiac Catheter First-In-Human Feasibility Study	14/02
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study	14/02
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium	31/01
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday	02/01
Pulse Biosciences Files FDA Notification to Advance Testing of New Cardiac Clamp	02/01
Pulse Biosciences Files 510(K) Submission with U.S. FDA for its CellFX nsPFA Cardiac Clamp	02/01
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp	02/01

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Pulse Biosciences, Inc.

Azioni

PLSE

US74587B1017

Altre lingue

Filtri